Liquiband deal with Stryker

RNS Number : 3633V

Advanced Medical Solutions Grp PLC

09 July 2009

 



For Immediate Release

9 July 2009

Advanced Medical Solutions Group plc

('AMS' or the 'Group')

Global partnership with Stryker for distribution of LiquiBand™ products in Cranio-maxillofacial surgery

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, today announces that it has entered into an agreement with Stryker Corporation ('Stryker') for global marketing and distribution of certain of its LiquiBand™ wound closure products for use in cranio-maxillofacial (CMF) surgical procedures. 

Stryker is one of the largest players in the $35.6 billion worldwide orthopaedic market with products sold in more than 120 countries. The CMF segment represents $900m of this market with Stryker being globally recognised as the leader in this specialist field which involves surgical procedures resulting from fracture repair and deformity correction in the head and neck.

Under the terms of the agreement announced today, Stryker will have exclusive marketing and distribution rights for predominantly all geographical markets for CMF, with product launches to the European market, where the products are approved, commencing this month and a phased roll out in the rest of the world following thereafter. Sales by Stryker into the US CMF market are expected to commence later this year following FDA approval of the relevant products. 

LiquiBand™ is a range of topical tissue adhesives based on cyanoacrylate adhesive technology developed for medical applications covering the whole spectrum of wound closure in the Emergency Room (ER) and Operating Room (OR).  Tissue adhesives offer significant benefits over conventional ways of closing wounds following trauma or surgical incisions. They are simple to use, non-invasive, help to reduce the risk of infection, minimise trauma to the patient and provide good clinical and cosmetic outcomes.

Commenting on this agreement, Dr. Don Evans, Chief Executive Officer of Advanced Medical Solutions, stated:

“Given the broad application for the current and future LiquiBand™ product portfolio, we believe that the optimal commercialisation strategy is via multiple partners with specific competencies and experience. I am therefore, delighted that we have been able to sign Stryker as our first global marketing and distribution partner, taking our LiquiBand™ technology into the CMF arena. As a leader in this surgical speciality, they are an ideal partner to create and develop this market for our products.”

For further information, please contact:

Advanced Medical Solutions Group plc
Don Evans, Chief Executive Officer Mary Tavener, Finance Director www.admedsol.com	Tel: [phone]
Buchanan Communications
Mark Court / Stasa Filiplic	Tel: [phone]
Investec Bank plc	Tel: [phone]
Richard Jones / Tim Pratelli

Notes to Editors:

Advanced Medical Solutions is a leading company in the development and manufacture of products for the $15 billion global woundcare market.

Founded in 1991 and quoted on AIM, Advanced Medical Solutions is focused on the design, development and manufacture of innovative products for advanced woundcare and wound closure.  

The advanced woundcare products are based on the moist wound healing principle.  AMS uses its inhouse technology to provide a vertically integrated 'one stop shop' for all categories of moist wound healing products. The Company has the capability to move a product from design and development through to production and delivery for distribution and sale into customer markets.

The acquisition of a 49.4% stake in Corpura BV in May 2008 strengthened AMS's position in hydrophilic polyurethane foam - the largest and fastest growing segment of the advanced woundcare market.

AMS' technology in cyanoacrylate based tissue adhesives is used for the closure of small cuts and trauma wounds through to large surgical incisions, and also for protecting or sealing skin to prevent breakdown or infection. 

AMS' products which currently serve the majority of the key global markets are sold either direct or through strategic partners and distributors. 

 

END

 

 

SALFGGGNKRFGLZM